Pharmala Biotech Holdings Inc. (MDMA.CN)
CAD 0.23
(-4.17%)
CAD 0.23
(-4.17%)
| Breakdown | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 532 Thousand | 78.07 Thousand | - |
| Cost of Revenue | 77.9 Thousand | 2288.00 | 303.00 |
| Gross Profit | 454.09 Thousand | 75.78 Thousand | -303.00 |
| Operating Expenses | 1.21 Million | 1.06 Million | 2.5 Million |
| Selling, General and Administrative Expenses | 1.15 Million | 1.04 Million | 2.5 Million |
| Research and Development Expenses | -166.52 Thousand | - | - |
| Other Expenses | 231.47 Thousand | - | - |
| Cost and Expenses | 1.29 Million | 1.06 Million | 2.5 Million |
| Operating Income | -762.95 Thousand | -985.58 Thousand | -2.5 Million |
| Interest Expense | - | - | - |
| Income Tax Expense | - | -3.00 | -2.08 Million |
| Earnings before Tax | -779.81 Thousand | -985.58 Thousand | -2.5 Million |
| Net Income | -779.81 Thousand | -985.58 Thousand | -2.5 Million |
| Earnings Per Share Basic | -0.01 | -0.01 | -0.03 |
| Earnings Per Share Diluted | -0.01 | -0.01 | -0.03 |
| Weighted Average Shares Outstanding | 84.52 Million | 82.99 Million | 82.99 Million |
| Weighted Average Shares Outstanding (Diluted) | 84.52 Million | 82.99 Million | 82.99 Million |
| Gross Margin | 0.85 | 0.97 | - |
| EBIT Margin | -1.33 | -12.47 | - |
| Profit Margin | -1.47 | -12.62 | - |
| EBITDA | -710.18 Thousand | -973.44 Thousand | -2.5 Million |
| Earnings Before Tax Margin | -1.43 | -12.62 | - |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 139.84 Thousand | 90.41 Thousand | 752.47 Thousand | 532 Thousand | 438.66 Thousand | - |
| Cost of Revenue | 281.04 Thousand | 15.77 Thousand | 292.95 Thousand | 77.9 Thousand | 77.9 Thousand | 13.17 Thousand |
| Gross Profit | -141.19 Thousand | 74.64 Thousand | 459.51 Thousand | 454.09 Thousand | 360.76 Thousand | -13.17 Thousand |
| Operating Expenses | 271.95 Thousand | 297.2 Thousand | 253.6 Thousand | 1.21 Million | 271.76 Thousand | 338.74 Thousand |
| Selling, General and Administrative Expenses | 265.9 Thousand | 265.03 Thousand | 176.99 Thousand | - | 354.23 Thousand | 300.06 Thousand |
| Research and Development Expenses | 6048.00 | 32.16 Thousand | 41.66 Thousand | - | -14.08 Thousand | - |
| Other Expenses | - | - | -169.43 Thousand | - | - | - |
| Cost and Expenses | 552.99 Thousand | 312.98 Thousand | 546.56 Thousand | 1.29 Million | 349.67 Thousand | 338.74 Thousand |
| Operating Income | -413.15 Thousand | -222.57 Thousand | 205.9 Thousand | -746.08 Thousand | 88.99 Thousand | -338.74 Thousand |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | 2.00 | 3.00 | -27.48 Thousand | 16.86 Thousand | -30.58 Thousand | -2.00 |
| Earnings before Tax | -413.15 Thousand | -222.56 Thousand | 36.47 Thousand | -779.81 Thousand | -80.3 Thousand | -338.74 Thousand |
| Net Income | -413.15 Thousand | -222.56 Thousand | 36.47 Thousand | -779.81 Thousand | -80.3 Thousand | -338.74 Thousand |
| Earnings Per Share Basic | -0.00 | -0.00 | 0.00 | - | -0.00 | -0.00 |
| Earnings Per Share Diluted | -0.00 | -0.00 | 0.00 | - | -0.00 | -0.00 |
| Weighted Average Shares Outstanding | 89.14 Million | 86.9 Million | 86.47 Million | 84.52 Million | 86.08 Million | 82.99 Million |
| Weighted Average Shares Outstanding (Diluted) | 89.14 Million | 86.9 Million | 86.47 Million | 84.52 Million | 86.08 Million | 82.99 Million |
| Gross Margin | -1.01 | 0.83 | 0.61 | 0.85 | 0.82 | - |
| EBIT Margin | -2.84 | -2.29 | 0.29 | - | 0.23 | - |
| Profit Margin | -2.95 | -2.46 | 0.05 | -1.47 | -0.18 | - |
| EBITDA | -397.37 Thousand | -206.79 Thousand | 221.69 Thousand | - | 102.22 Thousand | -325.56 Thousand |
| Earnings Before Tax Margin | -2.95 | -2.46 | 0.27 | -1.40 | 0.20 | - |
VALV
SYQH
MNXMF
BGEM
AGFAF
CBL